Skip to main content

Javier Hoyo Pérez

Institutions of which they are part

Administration and Management
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Javier Hoyo Pérez

Institutions of which they are part

Administration and Management
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Projects

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Malalties neurodegeneratives , Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, David Ramos Vicente, Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Alba Nicolau Vera, Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 30/06/2025

Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson's disease

IP: Miquel Vila Bover
Collaborators: Joan Compte Barrón, Javier Hoyo Pérez, Gerard Roch Alba, Marta González Sepúlveda, Ariadna Laguna Tuset, Joana Margalida Cladera Sastre
Funding agency: Michael J. Fox Foundation
Funding: 1269495.05
Reference: ASAP_MJFF2021
Duration: 01/11/2021 - 31/10/2024

UPcOmING - Unlock POtential of VHIR to INternationally Grow

IP: -
Collaborators: Sara Mas Assens, Javier Hoyo Pérez, Janna Anthonina Slabbekoorn
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 300000
Reference: SLT008/18/00203
Duration: 01/06/2019 - 31/12/2021

DECISION ON OPTIMAL COMBINATORIAL THERAPIES IN IMIDS USING SYSTEMS APPROACHES

IP: Sara Marsal Barril
Collaborators: Antonio Julia Cano, Javier Hoyo Pérez, Elena Granell Pallares, Adria Aterido Ballonga, Montse Sender Beleta
Funding agency: EUROPEAN COMMISSION
Funding: 1079085
Reference: DOCTIS_H2020_SC1-BHC2019
Duration: 01/01/2020 - 31/12/2025

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Maria José Evangelio Sequi

Maria José Evangelio Sequi

General Surgery
Read more
Esther Gil Barrionuevo

Esther Gil Barrionuevo

General Surgery
Read more
Mireia Verdaguer Tremolosa

Mireia Verdaguer Tremolosa

Research technician
General Surgery
Read more
Pablo Vilalta Gras

Pablo Vilalta Gras

Zelador/a
General Services and Infrastructures Unit
Manager
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.